🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

CSPC Ouyi Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with CSPC Ouyi Pharmaceutical as lead sponsor. Synced 26 Sep 2026
8Current trials
2Recruiting now
3Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

CSPC Ouyi Pharmaceutical is the lead sponsor of 8 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are SYH2069, Ropivacaine Hydrochloride and Tirzepatide. The most-studied condition is Overweight or Obesity.

ClinicalTrials.gov trials by status

  • Recruiting225%
  • Not yet open338%
  • Active, closed338%

Trials by phase

  • Phase 2338%
  • Phase 1338%
  • Phase 3225%
01

Clinical trials sponsored by CSPC Ouyi Pharmaceutical

8 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study Evaluating the Safety, Efficacy and Pharmacokinetics of SYH9089 Injection in Patients Undergoing Abdominal Surgery.
NCT07519109 · ClinicalTrials.gov ↗ · Postoperative Pain
Phase 1 Recruiting 2026-03 China
A Trial of Dextromethorphan and Bupropion Sustained-Release Tablets in Patients With Major Depressive Disorder
NCT06958692 · ClinicalTrials.gov ↗ · Major Depressive Disorder (MDD)
Phase 3 Recruiting 2025-04 China
A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011
NCT06354114 · Advanced Breast Cancer
Phase 2 Not yet open 2024-04 China
A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin
NCT07796477 · ClinicalTrials.gov ↗ · T2DM (Type 2 Diabetes Mellitus)
Phase 2 Not yet open 2026-11 China
Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.
NCT07803991 · ClinicalTrials.gov ↗ · Overweight or Obesity
Drug: SYH2069
Phase 2 Not yet open 2026-09 China
A Study of Prusogliptin Tablets Combined With Dapagliflozin Tablets and Metformin Hydrochloride Extended Release Tablets in Type 2 Diabetes
NCT07026968 · ClinicalTrials.gov ↗ · Type 2 Diabetes
Phase 3 Active, closed 2025-06 China
A Study of SYH2069 Injection in Healthy Participants
NCT07736391 · ClinicalTrials.gov ↗ · Overweight or Obesity, Diabetes
Drug: SYH2069
Phase 1 Active, closed 2026-01 China
A Study of SYH2082 Injection in Healthy Participants
NCT07736404 · ClinicalTrials.gov ↗ · Overweight or Obesity
Phase 1 Active, closed 2026-04 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in CSPC Ouyi Pharmaceutical trials

3 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in CSPC Ouyi Pharmaceutical trials

7 conditions
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China82

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Overweight or Obesity

SponsorTrials
Clinical Nutrition Research Center, Illinois Institute of Technology2
BrightGene Bio-Medical Technology2
Fujian Shengdi Pharmaceutical2
Innovent Biologics Technology Limited (Shanghai R&D Center)1
MindRank AI1
Suzhou Alphamab1

Sponsors with the most current trials registered for this condition.

06

Questions about CSPC Ouyi Pharmaceutical trials

How many clinical trials does CSPC Ouyi Pharmaceutical sponsor?

CSPC Ouyi Pharmaceutical is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are CSPC Ouyi Pharmaceutical trials recruiting?

Yes. 2 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is CSPC Ouyi Pharmaceutical testing?

Its current trials name 3 drugs and biologicals as interventions. The most frequent are SYH2069 (3), Ropivacaine Hydrochloride (1) and Tirzepatide (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.